ATE459883T1 - Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose - Google Patents

Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Info

Publication number
ATE459883T1
ATE459883T1 AT05715950T AT05715950T ATE459883T1 AT E459883 T1 ATE459883 T1 AT E459883T1 AT 05715950 T AT05715950 T AT 05715950T AT 05715950 T AT05715950 T AT 05715950T AT E459883 T1 ATE459883 T1 AT E459883T1
Authority
AT
Austria
Prior art keywords
diagnosis
cancer prognosis
proliferation markers
clinical practice
new proliferation
Prior art date
Application number
AT05715950T
Other languages
English (en)
Inventor
Genevieve Almouzni
Sophie E Polo
Stamatios E Theocharis
Philippe Vielh
Original Assignee
Inst Curie
Centre Nat Rech Scient
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Univ Paris Curie filed Critical Inst Curie
Application granted granted Critical
Publication of ATE459883T1 publication Critical patent/ATE459883T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05715950T 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose ATE459883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54811104P 2004-02-27 2004-02-27
PCT/EP2005/002578 WO2005085860A2 (en) 2004-02-27 2005-02-28 New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis

Publications (1)

Publication Number Publication Date
ATE459883T1 true ATE459883T1 (de) 2010-03-15

Family

ID=34919336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05715950T ATE459883T1 (de) 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Country Status (7)

Country Link
US (2) US7781174B2 (de)
EP (1) EP1721165B1 (de)
JP (1) JP4848355B2 (de)
AT (1) ATE459883T1 (de)
CA (1) CA2555656C (de)
DE (1) DE602005019694D1 (de)
WO (1) WO2005085860A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999253B1 (de) 2006-03-02 2019-05-22 Viacyte, Inc. Endokrine vorläuferzellen, pankreashormon-exprimierende zellen und herstellungsverfahren
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US20100144830A1 (en) * 2006-09-19 2010-06-10 Masahiko Kuroda Cancer cell identification marker and cancer cell proliferation inhibitor
CN101679294B (zh) 2007-05-30 2012-08-08 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2009126543A1 (en) 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Biomarker panel for prediction of recurrent colorectal cancer
EP2243843A1 (de) * 2009-04-24 2010-10-27 Institut Curie HP1-Alpha als prognostischer Marker bei Krebserkrankungen des Menschen
US20130149320A1 (en) 2010-05-31 2013-06-13 Centre National De La Recherche Scientifique Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
EP4060344A1 (de) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Verfahren und kits
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains
CA3058406A1 (en) 2017-03-30 2018-10-04 The Board Of Trustees Of The University Of Illinois Method and kit for diagnosing early stage pancreatic cancer
US12153054B2 (en) 2018-02-28 2024-11-26 Nitto Boseki Co., Ltd. Method for isolating cell nuclei having enhanced antigenicity from fixed cells or FFPE tissue section, and antigen activator and kit therefor
CN111766385B (zh) * 2020-07-06 2023-09-26 河南赛诺特生物技术有限公司 术中快速鉴别肺癌和硬化性肺细胞瘤的免疫组化试剂盒
CN113984483B (zh) * 2021-09-28 2023-10-20 福建医科大学 一种冰冻切片盖玻片贴片染色方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
KR100857735B1 (ko) * 2000-11-24 2008-09-12 에자이 알앤드디 매니지먼트 가부시키가이샤 항암제에 대한 종양 세포의 감수성을 검정하는 방법
WO2003025138A2 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2003217774A1 (en) * 2002-02-28 2003-09-16 Georgetown University Method and composition for detection and treatment of breast cancer

Also Published As

Publication number Publication date
DE602005019694D1 (de) 2010-04-15
WO2005085860A2 (en) 2005-09-15
CA2555656A1 (en) 2005-09-15
US7781174B2 (en) 2010-08-24
WO2005085860A3 (en) 2005-11-10
US20110003706A1 (en) 2011-01-06
JP2007524103A (ja) 2007-08-23
JP4848355B2 (ja) 2011-12-28
EP1721165A2 (de) 2006-11-15
EP1721165B1 (de) 2010-03-03
US20070077577A1 (en) 2007-04-05
CA2555656C (en) 2017-03-28

Similar Documents

Publication Publication Date Title
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
AU2007255110A8 (en) Circulating tumor cell assay
ATE519110T1 (de) Diagnostischer nanosensor und dessen verwendung in der medizin
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
BR112013006764A2 (pt) método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente
WO2008109414A3 (en) Use of endogenous fluorescence to identify invading metastatic breast tumor cells
NO20074817L (no) Epidermal vekstfaktorreseptor genkopiantall
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
EP3894868A4 (de) Kombinatorische zeitliche biomarker und präzisionsarzneimittel mit detektions- und behandlungsmethoden zur verwendung bei nervenläsionen, nervenerkrankungen und nervenreparaturen
MY193895A (en) Combination test for colorectal cancer
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE479898T1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602005024964D1 (de) Verfahren zur beurteilung der malignität einer säuger-krebszelle
WO2013072584A8 (fr) Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
BR102015015096A2 (pt) método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties